Case Studies


Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.

Below you’ll find our thought leadership library consisting of posters, sponsor success stories and webinars that highlight the Champions TumorGraft® technology, and its increasingly vital role in drug discovery and development for pharmaceutical and biotech organizations.


PDX Programs for Clinical Advancement of Oncology Agents, presented by Neal Goodwin, PhD, Vice President of Research Development


EORTC 2015

AACR 2015

AACR 2014

EORTC 2014

Sponsor Success Stories


Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology